Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.


Baliga, RS; Zhao, L; Madhani, M; Lopez-Torondel, B; Visintin, C; Selwood, D; Wilkins, MR; MacAllister, RJ; Hobbs, AJ; (2008) Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. American journal of respiratory and critical care medicine, 178 (8). pp. 861-9. ISSN 1073-449X DOI: https://doi.org/10.1164/rccm.200801-121OC

Full text not available from this repository.

Abstract

Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodilators in patients with pulmonary arterial hypertension. The mechanism(s) underlying this specificity remains unclear, but studies in genetically modified animals suggest it might be dependent on natriuretic peptide bioactivity.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
PubMed ID: 18689467
Web of Science ID: 259932600014
URI: http://researchonline.lshtm.ac.uk/id/eprint/1645

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
298Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item